Cornerstone Advisory’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-5,110
| Closed | -$505K | – | 244 |
|
|
2024
Q3 | $505K | Sell |
5,110
-1,586
| -24% | -$156K | 0.07% | 129 |
|
|
2024
Q2 | $621K | Sell |
6,696
-328
| -5% | -$29.4K | 0.09% | 112 |
|
|
2024
Q1 | $666K | Sell |
7,024
-1,400
| -17% | -$130K | 0.1% | 121 |
|
|
2023
Q4 | $752K | Sell |
8,424
-3,151
| -27% | -$234K | 0.12% | 104 |
|
|
2023
Q3 | $845K | Sell |
11,575
-7,917
| -41% | -$632K | 0.15% | 89 |
|
|
2023
Q2 | $1.62M | Sell |
19,492
-2,128
| -10% | -$178K | 0.28% | 52 |
|
|
2023
Q1 | $1.65M | Buy |
21,620
+500
| +2% | +$41.5K | 0.3% | 50 |
|
|
2022
Q4 | $1.75M | Sell |
21,120
-3,272
| -13% | -$265K | 0.35% | 50 |
|
|
2022
Q3 | $1.94M | Buy |
24,392
+1,050
| +4% | +$88.5K | 0.43% | 41 |
|
|
2022
Q2 | $1.73M | Sell |
23,342
-2,020
| -8% | -$152K | 0.4% | 44 |
|
|
2022
Q1 | $2.28M | Buy |
25,362
+4,881
| +24% | +$451K | 0.35% | 46 |
|
|
2021
Q4 | $2.29M | Buy |
20,481
+7,074
| +53% | +$853K | 0.33% | 51 |
|
|
2021
Q3 | $1.69M | Buy |
13,407
+5,500
| +70% | +$708K | 0.28% | 58 |
|
|
2021
Q2 | $1.07M | Buy |
7,907
+2,958
| +60% | +$389K | 0.18% | 91 |
|
|
2021
Q1 | $671K | Sell |
4,949
-167
| -3% | -$25K | 0.13% | 132 |
|
|
2020
Q4 | $720K | Buy |
5,116
+4
| +0.1% | +$512 | 0.15% | 116 |
|
|
2020
Q3 | $570K | Sell |
5,112
-402
| -7% | -$45.1K | 0.13% | 117 |
|
|
2020
Q2 | $617K | Sell |
5,514
-33,847
| -86% | -$3.33M | 0.16% | 100 |
|
|
2020
Q1 | $3.05M | Sell |
39,361
-6,418
| -14% | -$568K | 0.93% | 35 |
|
|
2019
Q4 | $4.36M | Sell |
45,779
-16,043
| -26% | -$1.39M | 0.9% | 34 |
|
|
2019
Q3 | $4.71M | Buy |
61,822
+5,440
| +10% | +$452K | 1.02% | 31 |
|
|
2019
Q2 | $4.95M | Buy |
56,382
+16,428
| +41% | +$1.4M | 1.07% | 32 |
|
|
2019
Q1 | $3.62M | Sell |
39,954
-12,435
| -24% | -$1.06M | 0.8% | 37 |
|
|
2018
Q4 | $3.76M | Buy |
52,389
+25,891
| +98% | +$2.09M | 0.99% | 32 |
|
|
2018
Q3 | $2.54M | Sell |
26,498
-1
| -0% | -$97 | 0.75% | 35 |
|
|
2018
Q2 | $2.52M | Sell |
26,499
-1,799
| -6% | -$165K | 0.83% | 32 |
|
|
2018
Q1 | $2.48M | Sell |
28,298
-16,900
| -37% | -$1.54M | 0.89% | 30 |
|
|
2017
Q4 | $3.84M | Buy |
45,198
+9,450
| +26% | +$792K | 1.31% | 22 |
|
|
2017
Q3 | $3.1M | Buy |
35,748
+21,120
| +144% | +$1.69M | 1.05% | 26 |
|
|
2017
Q2 | $1.13M | Buy |
14,628
+7,628
| +109% | +$541K | 0.38% | 52 |
|
|
2017
Q1 | $485K | Buy |
+7,000
| New | +$470K | 0.24% | 61 |
|
Other funds holding XBI
Cornerstone Advisory's XBI Position: Q4 2024 in Review
Cornerstone Advisory sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2024, closing a stake of 5,110 shares — an estimated $505K sold.
Cornerstone Advisory first reported a position in XBI in Q1 2017 and held it in 31 quarters. The position peaked at $4.95M in Q2 2019. 738 funds tracked by Wall St. Rank hold XBI as of Q4 2024.
- Cornerstone Advisory reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2024 after selling out during the quarter.
- Cornerstone Advisory sold 5,110 State Street SPDR S&P Biotech ETF shares in Q4 2024, an estimated $505K.
- Cornerstone Advisory first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and held it in 31 quarters.
- Cornerstone Advisory's State Street SPDR S&P Biotech ETF position peaked at $4.95M in Q2 2019.
- 738 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2024.
Based on Cornerstone Advisory's 13F filing for Q4 2024, filed 18 Feb 2025.